Evaluating metabolite-based biomarkers for early diagnosis of pancreatic cancer: a systematic review

G Perazzoli, OM García-Valdeavero, M Pena, J Prados… - Metabolites, 2023 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year
survival rates around 10%. The only curative option remains complete surgical resection, but …

A systematic review on metabolomics-based diagnostic biomarker discovery and validation in pancreatic cancer

NP Long, SJ Yoon, NH Anh, TD Nghi, DK Lim, YJ Hong… - Metabolomics, 2018 - Springer
Introduction Metabolomics is an emerging approach for early detection of cancer. Along with
the development of metabolomics, high-throughput technologies and statistical learning, the …

Meta-analysis reveals both the promises and the challenges of clinical metabolomics

HE Roth, R Powers - Cancers, 2022 - mdpi.com
Simple Summary A highly desirable approach to diagnose a human disease quickly and
easily is to identify a chemical, protein, or antibody in a biofluid like blood or urine that is …

Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study

R Zhao, S Ren, C Li, K Guo, Z Lu, L Tian, J He… - Cancer …, 2023 - Wiley Online Library
Background Early detection of pancreatic ductal adenocarcinoma (PDAC) may improve the
prognosis of patients. This study was to identify metabolic features of PDAC and to discover …

Discovery of pancreatic adenocarcinoma biomarkers by untargeted metabolomics

A Martín-Blázquez, C Jiménez-Luna, C Díaz… - Cancers, 2020 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal
cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection …

[HTML][HTML] Metabolomic biomarkers of pancreatic cancer: a meta-analysis study

KY Mehta, HJ Wu, SS Menon, Y Fallah, X Zhong… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is
no blood test for early detection and diagnosis of this disease. Several research groups …

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma

YY Cao, K Guo, R Zhao, Y Li, XJ Lv, ZP Lu… - Digital …, 2023 - journals.sagepub.com
Background Diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to the
lack of specific symptoms and screening methods. Only less than 10% of PDAC patients are …

[PDF][PDF] Metabolomics analysis of marker metabolites for patients with pancreatic cancer

A Zhang, H Sun, G Yan, Y Han, XJ Wang - Med. Chem, 2014 - scholar.archive.org
Metabolomics is a rapidly growing field of research used in the identification and
quantification of the small molecule metabolites within an organism, thereby providing …

Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer

S Urayama, W Zou, K Brooks… - … in Mass Spectrometry …, 2010 - Wiley Online Library
Poor outcome of pancreatic cancer necessitates development of an early diagnostic method
to reduce mortality. No reliable early diagnostic test for pancreatic cancer detection has …

[HTML][HTML] Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma

K Unger, KY Mehta, P Kaur, Y Wang, SS Menon… - Oncotarget, 2018 - ncbi.nlm.nih.gov
The availability of robust classification algorithms for the identification of high risk individuals
with resectable disease is critical to improving early detection strategies and ultimately …